Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
ISBT Sci Ser
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
Most research suggests protein targets of 1.0-1.2 grams per kilogram of body weight, or approximately 0.5 grams per pound, provide adequate support during weight loss
Factors such as metabolism and dosing affect its longevity
US$ 22.75
US$ 25.63
US$ 22.18
US$ 24.86
US$ 24.79
US$ 28.70
US$ 29.62
